$RKDA

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights – Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 m

Arcadia Biosciences (RKDA) will hold a virtual annual meeting on Sept. 10, 2026 to vote on eight proposals. Shareholders will consider issuing up to 3,993,296 common shares from Series A-1 Preferred Investment Options tied to a June 12, 2026 private placement, and authorizing a reverse split of 1-for-2 to 1-for-10 to regain Nasdaq’s $1 minimum bid compliance.

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001469443 false 0001469443 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01,

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 rkda-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 11, 2026 between Arcadia Biosciences, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on

Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.

Arcadia Biosciences filed an amendment to its 2025 annual report, detailing board and committee structure, executive and non-employee director compensation (including option grants), and related-party transactions, without updating previous financial results. Key figures include CEO Thomas J. Schaefer's 2025 total compensation of $300,001 and audit fees of $892,001. The report also highlights a January 2026 inducement transaction where major holders exercised preferred investment options for approximately $2.1 million in cash and received new preferred investment options.

Arcadia Biosciences (RKDA) reported a 26% decrease in its fourth-quarter revenue, though its net loss for the period narrowed. The article, sourced from Reuters, provides this financial update for the company.

Arcadia Biosciences (RKDA) has announced an agreement to immediately exercise certain preferred investment options at a reduced price of $2.575 per share, generating approximately $2.1 million in gross proceeds. In return, the company will issue new unregistered preferred investment options to purchase up to 1,617,190 shares at $2.325 per share. These funds are intended for working capital and general corporate purposes, with the offering expected to close around January 12, 2026.

RKDA stock saw a pre-market rise after the company received a merger termination notice from Roosevelt Resources. The specific reasons for the termination and RKDA's subsequent plans were not detailed in the provided content. Investors are reacting to this development, indicating its significance for the company's future.

-- Zola® year-to-date revenues increase 26% year over year ---- Arcadia gross profit margins exceed 30% for 11th straight quarter ---- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Arcadia Biosciences, Inc.® ( Nasdaq: RKDA ) , a producer and ...